随着对肺癌发病机制及其生物学特性研究的不断深入, 分子靶向治疗尤其是表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)在非小细胞肺癌治疗方面取得了突破性进展, 然而经过6～12个月的治疗后, 大部分患者会对EGFR-TKIs产生获得性耐药。PI3K/Akt/mTOR信号通路在非小细胞肺癌的发生发展中具有重要的作用, 该通路在肿瘤治疗方面已经有了比较广泛的研究。中药在对抗EGFR-TKIs耐药方面有很大的前景。就近年来中药通过抑制非小细胞肺癌PI3K/Akt/mTOR信号通路来克服EGFR-TKIs获得性耐药的研究进展进行综述。

With in-depth study of the pathogenesis of lung cancer and its biological behaviour, molecular targeted therapy, especially the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) made a breakthrough in non-small cell lung cancer treatment. However, the majority of patients can produce the resistance to EGFR-TKIs after 6 to 12 months treatment, which called acquired drug resistance. PI3K/Akt/mTOR pathway plays an important role in the development of non-small cell lung cancer, this pathway in cancer treatment has been widely studied. Chinese materia medica (CMM) in overcoming EGFR-TKIs resistance has a bright future, In this review, we show the developments on CMM in overcoming EGFR-TKIs acquired drugs resistance through PI3K/Akt/mTOR pathway.

国家自然科学基金面上项目(81173247)